Log in or register to see all Alerts
New HTA Decisions in France
June 2020
Drug name
VYNDAQEL® (tafamidis)
Decision date
Therapeutic area
Neurological conditions
Therapeutic sub area
Neurological conditions: general and other
Official notice date
Reimbursement %
Decision (SMR)
Decision (ASMR)
Minor improvement (IV)
VYNDAQEL® is indicated for the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurological deficit.
Decision Type
Reassessment of SMR and ASMR
The committee considered the actual benefit of VYNDAQEL® to be 'important' in the indication of the Marketing Authorisation. Considering: - observational data with methodological limitations that suggest, with a decline of several years, a maintenance of effectiveness, although the effect size cannot be characterised; - the lack of comparative data versus ONPATTRO® (patisiran) or TEGSEDI® (inotersen); - the reassuring tolerance profile, with a decline over several years; - partially covered medical need in this rare disease; it was concluded that VYNDAQEL® provides a minor improvement in the medical service rendered (ASMR IV) in the therapeutic strategy which includes symptomatic management (excluding ONPATTRO® and TEGSEDI®). The committee proposed 100% reimbursement.